Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-025-04832-2
Abstract: Isatuximab, an immunoglobulin G monoclonal antibody that targets a specific CD38 epitope, is approved in combination with dexamethasone plus either pomalidomide or carfilzomib for treatment of adults with relapsed or refractory (R/R) multiple myeloma. Isatuximab… read more here.
Keywords: isatuximab; aged months; pediatric patients; population pharmacokinetics ... See more keywords
Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg.
Sign Up to like & getrecommendations! Published in 2023 at "Hematology"
DOI: 10.1080/16078454.2023.2182098
Abstract: BACKGROUND & OBJECTIVE Anti-CD38 targeting has become an important pillar of the treatment for patients with multiple myeloma (MM). This evolution was spearheaded by daratumumab, but more recently isatuximab became the second CD38-directed monoclonal antibody… read more here.
Keywords: isatuximab; experience isatuximab; isatuximab based; treatment ... See more keywords
Efficacy and Safety of Isatuximab Combination Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
Sign Up to like & getrecommendations! Published in 2025 at "Cancers"
DOI: 10.3390/cancers17213494
Abstract: Simple Summary Multiple myeloma is a type of blood cancer that often returns after initial treatment, creating a need for more effective therapies. Isatuximab is a newer antibody drug that helps the patient’s own immune… read more here.
Keywords: multiple myeloma; analysis; isatuximab; safety ... See more keywords